HQ SPCLT PHARMA
Big PharmaHQ SPCLT PHARMA is a major pharmaceutical company focused on Cardiovascular, Neurology, Oncology. Key products include DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE.
HQ SPCLT PHARMA's Key Drugs
HQ SPCLT PHARMA's core commercial portfolio centers on DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.
HQ SPCLT PHARMA's Recent FDA Approvals
HQ SPCLT PHARMA secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
HQ SPCLT PHARMA's Therapeutic Areas
HQ SPCLT PHARMA's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
HQ SPCLT PHARMA's Top Competitors
HQ SPCLT PHARMA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and GE HEALTHCARE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
HQ SPCLT PHARMA Pipeline Snapshot
Active clinical trials for HQ SPCLT PHARMA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (1)
Company Info
- First Approval
- 1978-12-19
- Latest
- 2026-05-01
- Applications
- 15